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S U M M A R Y
Background: Outcomes of community-acquired pneumonia (CAP) in relation to CD4+ cell counts have
not been established. We examined the correlation of CD4+ cell count and HIV-RNA level with the
clinical outcomes of CAP in hospitalized HIV-infected patients.
Methods: This was a retrospective study of 127 adult hospitalized patients with HIV infection enrolled
with the CAP Organization (CAPO), examining the time to clinical stability (TCS), length of hospital stay
(LOS), and all-cause mortality.
Results: Mortality data were available for 117 HIV-infected patients with CAP. Death within 28 days was
reported in 28 patients. The risk of mortality at 28 days was not signiﬁcant when adjusted for CD4+ cell
count (p = 0.123), HIV-RNA <400–1000 copies/ml (p = 0.093), HIV-RNA 1000–10 000 copies/ml
(p = 0.543), and HIV-RNA 10 000–100 000 copies/ml (p = 0.383). The propensity-adjusted Cox
proportional hazards regression models did not show any statistically signiﬁcant differences in LOS or
TCS for CD4+ cell counts (p = 0.590 and p = 0.420, respectively) or HIV-RNA levels (p = 0.470 and
p = 0.080, respectively). Multivariable Cox proportional hazards models did not reveal any statistically
signiﬁcant relationships between CD4+ cell counts or HIV-RNA levels with LOS or TCS.
Conclusions: Our study shows that clinical outcomes of HIV-infected patients with CAP are not predicted
by CD4+ cell counts or HIV-RNA levels after adjusting for confounders. The management of CAP in
patients with HIV infection should not be based on CD4+ cell counts or HIV-RNA levels of the HIV
infection.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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HIV infection is a major risk factor for the development of
community-acquired pneumonia (CAP).1–3 Streptococcus pneumo-
niae is the most common pathogen of bacterial pneumonia in HIV
patients.4 An association has been established between a high risk
of CAP in HIV-infected patients and low CD4+ cell counts;4–7
however CAP outcomes in relation to CD4+ cell counts in these
patients remain controversial.8–10 Some reports have indicated the
increased morbidity and mortality of HIV-infected patients with
CAP,11,12 therefore physicians may consider that it is safer to* Corresponding author.
E-mail address: jbordon@provhosp.org (J. Bordon).
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doi:10.1016/j.ijid.2011.05.021hospitalize these patients.13,14 A nationwide Danish cohort study
from 1995 to 2007 showed that HIV infection remains a major
indication for the need of hospitalization in patients with
pneumonia.15 First-time hospitalization for pneumonia was six-
fold greater among HIV-infected patients compared with the
general population until 2007.15 Because the clinical outcomes of
HIV-infected patients with CAP remain unknown, the need for and
beneﬁts of hospitalization in these patients are contentious.
Effective antiretroviral therapy (ART) has been shown to prevent
CAP among HIV-infected patients.15,16 However, bacterial pneumo-
nia was reported to be a major source of morbidity in HIV-infected
patients regardless of ART in a cohort of patients with CD4+ cell
counts of >350/mm3.16 Poorer outcomes among HIV-infected
patients with CAP are likely due to limited healthcare resources
for patients with advanced HIV disease and severity of illness.11,12ses. Published by Elsevier Ltd. All rights reserved.
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levels with clinical outcomes of hospitalized HIV-infected patients
with CAP may guide clinicians to optimize management and the
use of resources. The clinical outcomes of CAP in relation to CD4+
cell count, HIV-RNA level, and type of ART have not been fully
examined. This study examined the correlation of CD4+ cell count,
HIV-RNA level, and type of ART on the clinical outcomes of CAP
among hospitalized HIV-infected patients.
2. Materials and methods
2.1. Study design
This was a retrospective study of adult patients with HIV
infection hospitalized with CAP enrolled in the Community-
Acquired Pneumonia Organization (CAPO) database. This study
examined the outcomes: mortality at 28 days, the length of hospital
stay (LOS), and the time to clinical stability (TCS) in relation to CD4+
cell count and HIV-RNA level. The CAPO study protocol has been
approved by each local institutional review board of the CAPO
centers. Patients were enrolled from six centers: Louisville, KY, USA;
Washington, DC, USA; Orlando, FL, USA; Vigo, Spain; Tarragona,
Spain; and Barcelona, Spain. CAPO is an international, retrospective,
observational study of adult patients hospitalized with CAP. Random
medical records of hospitalized patients with the diagnosis of CAP
were reviewed at each participating center. Conﬁrmation of HIV
infection was obtained from the medical history. Each investigator
ﬁlled out a case report form that was transferred via the internet to
the CAPO study center at the University of Louisville. A sample of the
data collection form is available at the study website (http://
www.caposite.com). Validation of data quality was performed at the
study center before the case was entered into the CAPO database.
These CAPO study cases were enrolled from June 6, 2001 to January
5, 2010. These study cases were from centers in the USA and Spain;
they received medical management according to national guidelines
and were expected to receive similar antibiotic treatment and
overall medical management.
2.2. Inclusion criteria
The diagnosis of CAP was according to the Infectious Diseases
Society of America/American Thoracic Society (IDSA/ATS) crite-
ria.17 CD4+ cell counts and HIV-RNA levels were obtained: CD4+
cell counts available at least once at 12, 6, or 3 months before
hospitalization and at the time of hospitalization for CAP; HIV-RNA
levels if available within the 12 months before hospitalization and
at the time of hospitalization for CAP.
ART was deﬁned as a combination of antiretrovirals including
two nucleoside drugs plus either one non-nucleoside drug or one
protease inhibitor. Salvage ART was not considered an exclusion
criterion. Information on antimicrobial therapy prior to hospitali-
zation for Pneumocystis jirovecii pneumonia (PCP) and Mycobacte-
rium avium complex was obtained.
2.3. Exclusion criteria
Patients with a presumptive or deﬁnitive diagnosis of PCP,
mycobacterial, or fungal pneumonia were excluded from this
study. Patients were excluded if they were treated for a suspected
PCP, mycobacterial, or fungal etiology.
2.4. Study outcomes
The study outcomes were: (1) TCS: a patient was deﬁned as
clinically stable and ready to be switched to an oral antibiotic the
day that the following four criteria were met: (a) improved coughand shortness of breath, (b) lack of fever for at least 8 h,
(c) improving leukocytosis (decreased at least 10% from the
previous day), and (d) tolerating oral intake with adequate
gastrointestinal absorption.18 Patients were evaluated daily within
the ﬁrst 7 days of hospitalization to determine the day when clinical
stability was reached. (2) LOS: deﬁned in days and calculated for
each patient as the day of discharge minus the day of admission.
Patients hospitalized for more than 14 days were censored at 15 days
in an effort to capture LOS data related only to CAP. (3) All-cause
mortality: patients were categorized as ‘survivor’ or ‘non-survivor’
and patients who were still hospitalized at day 28 were considered as
survivors.
2.5. Confounding variables
The following 28 variables were obtained from each study
participant: demographics: age, gender, and nursing home
residency; coexisting conditions: neoplastic disease, chronic
obstructive pulmonary disease (COPD), diabetes mellitus, renal
disease, liver disease, use of alcohol and/or illegal drugs,
cerebrovascular accident (CVA), and congestive heart failure
(CHF); physical examination: temperature, respiratory rate, heart
rate, blood pressure, and altered mental status; laboratory tests:
sodium, arterial partial pressure of O2, hematocrit, blood urea
nitrogen (BUN), glucose, and arterial pH; chest X-ray: multilobar
involvement, presence of cavity, and presence of pleural effusion;
severity of CAP: need for intensive care unit (ICU) admission, risk
class according to the pneumonia severity index (PSI), and CRB-65
score.19 Arterial partial pressure of O2 and arterial pH were done
only if patients were admitted to the ICU.
2.6. Statistical methods
The predictor variables in this study were CD4+ cell count and
HIV-RNA level. The CD4+ cell count and the HIV-RNA level were
utilized as both continuous variables and categorical variables. The
categorical CD4+ cell count was expressed using the following
cutoffs: <50 cells/mm3, 51–200 cells/mm3, 201–350 cells/mm3, and
>350 cells/mm3. The categorical HIV-RNA level was expressed using
the following cutoffs: <400 copies/ml, 401–10 000 copies/ml, and
>10 000 copies/ml. The primary outcome variable was mortality at
28 days, and the secondary outcome variables were LOS and TCS.
Baseline patient characteristics were compared between those
who survived until 28 days and those who had died within 28 days.
Categorical variables were compared using the Chi-square test or
Fisher’s exact test, and continuous variables were compared using
Mann–Whitney U-tests.
For the time-to-event outcomes of LOS and TCS, Kaplan–Meier
survival curves were created to compare the above-mentioned
cutoffs of CD4+ cell count and HIV-RNA level. Log-rank tests were
used to compare statistically signiﬁcant differences between the
survival curves.
Considering the relatively small sample size of this study,
traditional statistical methodology for adjustment of confounding
variables would have limited the ability to adjust for multiple
confounding variables in multivariate analyses. To overcome this
statistical limitation, a propensity score was created from all
demographic and clinical variables with p-values of 0.05. This
propensity score was then used to adjust for the possibility of
confounding effects in a series of regression models.
For the primary outcome of mortality at 28 days, propensity-
adjusted logistic regression models were used to evaluate the risk
of mortality for a given CD4+ cell count or HIV-RNA level, as well as
for the patient’s PSI. Predicted probabilities from each regression
model were used to create line charts to examine the trends in risk
of mortality.
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TCS, propensity-adjusted Cox proportional hazards regression
models were used. Hazard ratios and 95% conﬁdence intervals
were calculated to express the relative likelihood of the outcome forTable 1
Baseline characteristics of HIV-infected patients with CAP according to survival status 
Variable Dead a
(n = 28
Demographics
Age (years), mean (SD) 42.9 (7
Male gender 24 (85
Nursing home residence 2 (7.1)
Comorbidities and other risk factors
Altered mental status 3 (10.7
Aspiration pneumonia 2 (7.1)
BMI (kg/m2), mean (SD) 23.1 (4
Obesity (BMI >30) 0 (0) 
COPD 6 (21.4
CHF 0 (0) 
Cerebrovascular accident 0 (0) 
Diabetes mellitus 6 (21.4
Liver disease 2 (7.1)
Neurological disease 3 (10.7
Neoplastic disease 2 (7.1)
Previous CAP 7 (25)
Previous PCP 6 (21.4
Renal disease 6 (21.4
Substance use
Cocaine 0 (0) 
Crack 1 (3.6)
Heroin 1 (3.6)
Marijuana 3 (10.7
Methadone 0 (0) 
Alcohol 4 (14.3
Bacteremia 4 (14.3
Severity of disease
ICU admission 7 (25)
PSI class IV or V 3 (10.7
CRB-65 class II, III or IV 3 (10.7
HIV-speciﬁc variables
AIDS-deﬁning illness 10 (35
CD4+ (cells/mm3)
<200 19 (67
200–350 2 (7.1)
351–500 2 (7.1)
>500 5 (17.9
CD4+ cell %, mean (SD) 2.7 (1.
CD4+ cell absolute, mean (SD) 164.8 
CD4+ cells at CAP, mean (SD) 239.6 
CD4+ cells at 3 months before CAP, mean (SD) 246 (2
CD4+ cells at 6 months before CAP, mean (SD) 377 (3
CD4+ cells at 12 months before CAP, mean (SD) 338.1 
CD4+ cells <200 at 3 months before CAP 4/10 (
CD4+ cells <200 at 12 months before CAP 8/24 (
Detectable HIV-RNA level at CAP 23/25 
HIV-RNA level at CAP (copies/ml), mean (SD) 173 43
HIV-RNA level >100 000 copies/ml at CAP 8/25 (
HIV-RNA level 12 months after CAP (copies/ml), mean (SD) 200 98
HIV treatment
ART 21 (75
Protease inhibitor-based ART 10 (35
ART duration <2 months 2 (7.1)
ART duration <6 months 1 (3.6)
ART duration <12 months 13 (46
Prophylaxis
PCP prophylaxis 15 (53
PCP prophylaxis <3 months 16 (57
PCP prophylaxis <6 months 14 (50
Atovaquone 0 (0) 
Dapsone 2 (7.1)
Trimethoprim/sulfamethoxazole 9 (32.1
MAC prophylaxis 5 (17.9
Azithromycin 7 (25)
CAP, community-acquired pneumonia; SD, standard deviation; BMI, body mass index;
Pneumocystis jirovecii pneumonia; ICU, intensive care unit; PSI, pneumonia severity ind
a From a total of 127 patients enrolled in this study, 10 patients were excluded fromthe categorized values of CD4+ cell count and HIV-RNA level.
p-Values of 0.05 were considered statistically signiﬁcant in all
analyses. SAS v9.2 (SAS Inc., Cary, NC, USA) and MedCalc v11
(MedCalc Software, Mariakerke, Belgium) were used for all analyses.at 28 days of hospitalizationa
t 28 days
), n (%)
Alive at 28 days
(n = 89), n (%)
p-Value
.9) 43.8 (9.1) 0.643
.7) 56 (62.9) 0.083
 0 (0) 0.014
) 14 (15.7) 0.451
 3 (3.4) 0.437
.5) 27.9 (40.6) 0.297
11 (12.4) 0.269
) 11 (12.4) 0.291
4 (4.5) 0.238
3 (3.4) 0.309
) 7 (7.9) 0.066
 30 (33.7) 0.004
) 11 (12.4) 0.730
 2 (2.2) 0.246
 10 (11.2) 0.955
) 3 (3.4) 0.159
) 4 (4.5) 0.008
10 (11.2) 0.057
 9 (10.1) 0.253
 3 (3.4) 1.000
) 8 (9.0) 0.855
2 (2.2) 0.410
) 3 (3.4) 0.043
) 10 (11.2) 0.740
 8 (9.0) 0.039
) 13 (14.6) 0.759
) 25 (28.1) 0.060
.7) 6 (6.7) 0.252
.9) 49 (55.1) 0.320
 17 (19.1)
 12 (13.5)
) 11 (12.4)
5) 12.8 (8.7) 0.053
(213.6) 239.2 (250.6) 0.315
(286.4) 230.1 (207.6) 0.406
90.5) 280 (196.5) 0.688
96.6) 291.9 (173.7) 0.443
(390.2) 250.6 (208.8) 0.348
40) 6/12 (50) 0.639
33.3) 37/85 (43.5) 0.370
(92) 44/61 (72.1) 0.044
8.8 (229 706.2) 159 420.6 (440 566.3) 0.848
32) 16/60 (26.7) 0.619
5 (275 648.1) 212186.5 (722 485.3) 0.931
) 61 (68.5) 0.494
.7) 41 (46.1) 0.196
 3 (3.4) 0.429
 3 (3.4) 1.000
.4) 28 (31.5) 0.225
.6) 37 (41.6) 0.275
.1) 37 (41.6) 0.249
) 55 (61.8) 0.175
1 (1.1) 0.562
 4 (4.5) 0.629
) 28 (31.5) 0.910
) 11 (12.4) 0.240
 11 (12.4) 0.141
 COPD, chronic obstructive pulmonary disease; CHF, congestive heart failure; PCP,
ex; ART, antiretroviral therapy; MAC, Mycobacterium avium complex.
 the analysis of outcome mortality because mortality data were not available.
Figure 1. Propensity-adjusted risk of mortality at 28 days with 95% conﬁdence
intervals by CD4+ cell count for patients hospitalized with community-acquired
pneumonia.
Figure 2. Propensity-adjusted risk of mortality at 28 days with 95% conﬁdence
intervals by HIV-RNA level for patients hospitalized with community-acquired
pneumonia.
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A total of 127 HIV-infected patients with CAP were enrolled in
this study. Ten patients did not have mortality data and wereFigure 3. Kaplan–Meier survival curves indicating length of hospital stay (LOS) by (A) C
acquired pneumonia.excluded from the analysis of mortality outcome. Death within 28
days was reported for 28 patients. The main characteristics of
survivors and non-survivors are shown in Table 1. The presence of
AIDS was not statistically different between non-survivors
(35.7%) and survivors (6.7%). More than half of the patients in
both groups had CD4+ cell counts of <200 mm3. There was no
signiﬁcant difference between the groups in CD4+ cell counts
regardless of cutoffs, means, and counts in the 12 months
preceding CAP; however the CD4+ cell percent was lower for non-
survivors (p = 0.053). Both groups had similar mean CD4+ cell
counts at the time of CAP: 239.6  286.4 for non-survivors and
230.1  207.6 for survivors. At the time of diagnosis of CAP, 92% of
non-survivors had a detectable HIV-RNA level versus 72.1% of
survivors (p = 0.044). The mean HIV-RNA load at CAP was 173 438
copies/ml for non-survivors and 159 420 copies/ml for survivors
(p = 0.848).
The etiology of CAP was identiﬁed in 36 (28.3%) of 127 study
cases. The pathogens identiﬁed were S. pneumoniae (n = 22),
methicillin-resistant Staphylococcus aureus (n = 5), methicillin-
susceptible S. aureus (n = 1), coagulase-negative Staphylococcus
(n = 1), Pseudomonas aeruginosa (n = 4), Legionella spp (n = 1),
inﬂuenza A 2009 H1N1 (n = 1), and adenovirus (n = 1).
The propensity-adjusted logistic regression models did not
show any statistically signiﬁcant difference in the risk of
mortality at 28 days for the cohort of HIV-infected patients
with CAP according to CD4+ cell count (p = 0.123) (Figure 1). The
risk of mortality at 28 days was not signiﬁcant when adjusted
for HIV-RNA levels at three different ranges: HIV-RNA <400–
1000 copies/ml (p = 0.093), HIV-RNA 1000–10 000 copies/ml
(p = 0.543), and HIV-RNA 10 000–100 000 copies/ml (p = 0.383)
(Figure 2). The propensity-adjusted Cox proportional hazards
regression models did not reveal any statistically signiﬁcant
difference in LOS for CD4+ cell counts (p = 0.590) or HIV-RNA
levels (p = 0.470) (Figure 3). There was no signiﬁcant difference
in the likelihood of TCS in relation to CD4+ cell count (p = 0.420)
or HIV-RNA level (p = 0.080) (Figure 4). Multivariable Cox
proportional hazards models did not reveal any statistically
signiﬁcant relationships between CD4+ cell counts or HIV-RNA
levels with LOS or TCS (Tables 2 and 3).D4+ cell count and (B) HIV-RNA level, for patients hospitalized with community-
Figure 4. Kaplan–Meier survival curves indicating time to clinical stability (TCS) by (A) CD4+ cell count and (B) HIV-RNA level, for patients hospitalized with community-
acquired pneumonia.
Table 2
Length of stay (LOS), propensity-adjusted Cox proportional hazards models
Predictor variable Measurement Hazard ratio 95% CI p-Value
CD4+ cells/mm3 <50 0.673 0.26–1.742 0.414
50–200 0.791 0.354–1.766 0.566
201–350 0.506 0.176–1.454 0.206
>350 Reference Reference Reference
HIV-RNA copies/ml 0–400 1.421 0.757–2.666 0.274
401–10 000 0.851 0.392–1.846 0.683
>10 000 Reference Reference Reference
CI, conﬁdence interval.
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Our study indicates that the mortality of hospitalized HIV-
infected patients with CAP is not predicted by the CD4+ cell counts
or HIV-RNA levels after adjusting for confounders. Jordano et al.
reported similar mortality in patients with invasive pneumococcal
disease with CD4+ cell counts of >200 vs. 200 cells/ml without
adjusting for confounders.8 Others have reported a signiﬁcantly
greater mortality in HIV-infected patients with CAP in relation to
CD4+ cell counts of <200 cells/ml.11 In a study reported by Feldman
et al. that included 83% of patients from South Africa, a high
mortality of patients was associated with HIV infection and CAP.12
The higher mortality in relation to the low CD4+ cell count could be
related to the fact that this study examined only bacteremic
pneumococcal pneumonia and that there were likely other
unknown factors.12 Our study was largely represented by
middle-aged individuals with advanced HIV infection, as reﬂected
by the fact that more than half of the patients in both the survivor
and non-survivor groups had CD4+ cell counts of 200/ml. HIV-
infection is primarily driven by abnormalities in CD4+ cells and to aTable 3
Time to clinical stability (TCS), propensity-adjusted Cox proportional hazards models
Predictor variable Measurement Haz
CD4+ cells/mm3 <50 0.7
50–200 0.9
201–350 0.8
>350 Ref
HIV-RNA copies/ml 0–400 1.7
401–10 000 1.0
>10 000 Ref
CI, conﬁdence interval.lesser extent by abnormalities in humoral and innate immunity
including neutrophils.20–22 In contrast to eosinophils,23 neutro-
phils play a major role in the lung inﬂammatory changes of
pneumonia;24 therefore CAP outcomes are not expected to be
affected among HIV-infected patients. The lack of correlation of
CD4+ cell counts with mortality found in our study suggests that
factors other than CD4+ cells contribute to the host response in CAP
and mortality. Our results may help clinicians to consider that the
mortality of HIV-infected patients with CAP cannot be anticipated
by CD4+ cell counts.
In a multivariable analysis, Malinis et al. reported a similar TCS
in patients with CAP regardless of their HIV status.10 In this study, a
CD4+ cell count was present for 57% of patients.10 Similarly, our
propensity-adjusted Cox proportional regression models did not
show any signiﬁcant difference in TCS in relation to CD4+ cell count
or HIV-RNA level (Figure 4). Differences in LOS have been reported
among patients with CAP in relation to the CD4+ cell count.8,11 In
underdeveloped countries, LOS is expected to be affected by the
presence of advanced HIV diseases associated with malnourish-
ment and limited healthcare resources that would stabilize theard ratio 95% CI p-Value
86 0.307–2.009 0.614
81 0.447–2.154 0.961
03 0.292–2.209 0.670
erence Reference Reference
8 0.952–3.331 0.071
02 0.493–2.034 0.997
erence Reference Reference
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affected by evolving medical management to decrease the LOS. Our
study failed to predict the LOS of patients with CAP adjusted by CD4+
cell count or HIV-RNA level. Our results suggest that TCS and LOS are
driven by factors other than CD4+ cell count and HIV-RNA levels.
Our study has important limitations. This was a retrospective
non-longitudinal study of cases randomly selected from CAPO
centers. Therefore, our results need to be validated in a prospective
study. A major strength of our study is the utilization of
multivariate techniques and a propensity score to adjust potential
confounders to more precisely measure the impact of CD4+ cell
count and HIV-RNA level on clinical outcomes. PSI and CRB-65
have been validated for the outcomes of CAP in HIV-uninfected
individuals but not for HIV-infected individuals with CAP,
therefore our data measuring the severity of CAP in HIV-infected
individuals may not be optimal. Because many of our study cases
were not admitted to the ICU, it was not possible to obtain APACHE
II scores. Finally, our study does not report tobacco smoking given
the difﬁculty in obtaining optimal data on tobacco smoking.
In conclusion, our study shows that the clinical outcomes of
HIV-infected patients hospitalized with CAP are not predicted by
the CD4+ cell counts or HIV-RNA levels after adjusting for
confounders. Clinicians should be aware that the clinical outcomes
and management of CAP in patients with HIV infection should not
be based on CD4+ cell counts or HIV-RNA levels.
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